Michael S. Gordon
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 140
- Cancer Immunotherapy and Biomarkers 53
- CAR-T cell therapy research 26
- Cancer Treatment and Pharmacology 22
- Colorectal Cancer Treatments and Studies 19
-
- Angiogenesis and VEGF in Cancer 20
- Melanoma and MAPK Pathways 19
- Co-authors
- David S. Mendelson (38 shared papers)Kim Margolin (5 shared papers)Jeffrey R. Infante (32 shared papers)Michael B. Atkins (9 shared papers)Ann A. Jakubowski (8 shared papers)Jeffrey A. Sosman (7 shared papers)Wilson H. Miller (5 shared papers)Razelle Kurzrock (11 shared papers)
- Journals
- Journal of Clinical Oncology (103 papers)Annals of Oncology (24 papers)Cancer Research (15 papers)Clinical Cancer Research (15 papers)Molecular Cancer Therapeutics (11 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Michael S. Gordon
320 papers receiving 15.0k citations
Michael S. Gordon's Hit Papers
Peers
Comparison fields: 5 of 165
- Oncology 6.8k
- Immunology 3.0k
- Hematology 1.4k
- Cancer Research 1.6k
- Pulmonary and Respiratory Medicine 2.9k
Countries citing papers authored by Michael S. Gordon
This map shows the geographic impact of Michael S. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Gordon more than expected).
Fields of papers citing papers by Michael S. Gordon
This network shows the impact of papers produced by Michael S. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Gordon. The network helps show where Michael S. Gordon may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael S. Gordon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 325 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid) Hit paper breakdown → | 1991 | 1055 |
| 2 | Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer Hit paper breakdown → | 2001 | 746 |
| 3 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer Hit paper breakdown → | 2016 | 663 |
| 4 | Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2004 | 602 |
| 5 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 583 |
| 6 | Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. | 1997 | 460 |
| 7 | Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Hit paper breakdown → | 2017 | 437 |
| 8 | 2012 | 431 | |
| 9 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study Hit paper breakdown → | 2016 | 412 |
| 10 | 2010 | 377 | |
| 11 | Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Hit paper breakdown → | 2019 | 326 |
| 12 | 2005 | 304 | |
| 13 | 2002 | 298 | |
| 14 | 2007 | 266 | |
| 15 | A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. | 1996 | 220 |
| 16 | 2003 | 210 | |
| 17 | 2018 | 209 | |
| 18 | 2006 | 187 | |
| 19 | 2001 | 169 | |
| 20 | 2001 | 157 |
About Michael S. Gordon
Michael S. Gordon is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 325 papers that have together received 15.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (53 papers), CAR-T cell therapy research (26 papers), Renal cell carcinoma treatment (25 papers), Monoclonal and Polyclonal Antibodies Research (23 papers), Cancer Treatment and Pharmacology (22 papers), Angiogenesis and VEGF in Cancer (20 papers), Colorectal Cancer Treatments and Studies (19 papers) and Melanoma and MAPK Pathways (19 papers). The work is most often cited by research in Oncology (6.8k citations), Immunology (3.0k citations), Hematology (1.4k citations), Cancer Research (1.6k citations) and Pulmonary and Respiratory Medicine (2.9k citations). Michael S. Gordon has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include David S. Mendelson, Kim Margolin, Jeffrey R. Infante, Michael B. Atkins, Ann A. Jakubowski, Jeffrey A. Sosman, Wilson H. Miller, Razelle Kurzrock, George W. Sledge and Janice Gabrilove. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.